We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
51
Zymeworks
ZYME
$2.05B
$13.4M 0.08%
1,708,472
– –
WHWK
52
Whitehawk Therapeutics
WHWK
$270M
$12.7M 0.08%
989,928
– –
CABA icon
53
Cabaletta Bio
CABA
$531M
$12.4M 0.07%
1,344,000
+681,937
+103% +$2.48M
VSTM icon
54
Verastem
VSTM
$624M
$10.9M 0.07%
2,249,075
– –
ALT icon
55
Altimmune
ALT
$605M
$10.8M 0.06%
653,562
-1,116,119
-63% -$12.5M
STOK icon
56
Stoke Therapeutics
STOK
$2.08B
$10.2M 0.06%
1,108,913
+739,586
+200% +$7.69M
CINC
57
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$9.92M 0.06%
807,212
– –
VOR icon
58
Vor Biopharma
VOR
$1.38B
$9.75M 0.06%
73,296
– –
RNAM
59
DELISTED
Avidity Biosciences
RNAM
$9.65M 0.06%
+434,782
New +$6.48M
PACB icon
60
Pacific Biosciences
PACB
$420M
$9.23M 0.06%
1,127,782
– –
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.52M 0.05%
1,169,103
– –
RETA
62
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.51M 0.05%
223,976
– –
SMMT icon
63
Summit Therapeutics
SMMT
$10.5B
$8.5M 0.05%
+2,000,000
New +$3.64M
VERU icon
64
Veru
VERU
$45M
$8.5M 0.05%
160,958
– –
AFMD
65
DELISTED
Affimed
AFMD
$8.18M 0.05%
659,683
– –
CMPX icon
66
Compass Therapeutics
CMPX
$432M
$7.83M 0.05%
+1,557,630
New +$6.21M
DSGN icon
67
Design Therapeutics
DSGN
$938M
$7.1M 0.04%
692,131
-744,505
-52% -$10.1M
BHVN icon
68
Biohaven
BHVN
$2.09B
$6.61M 0.04%
+476,190
New +$6.72M
VERA icon
69
Vera Therapeutics
VERA
$2.33B
$6.45M 0.04%
333,333
– –
ALEC icon
70
Alector
ALEC
$264M
$6.29M 0.04%
681,991
+442,763
+185% +$3.86M
MGNX icon
71
MacroGenics
MGNX
$261M
$5.99M 0.04%
892,579
– –
LONA
72
LeonaBio Inc
LONA
$72.4M
$5.96M 0.04%
187,984
+83,901
+81% +$2.64M
IPSC icon
73
Century Therapeutics
IPSC
$375M
$5.9M 0.04%
1,149,340
+778,753
+210% +$7.35M
ROIV icon
74
Roivant Sciences
ROIV
$26.2B
$5.73M 0.03%
+716,653
New +$3.99M
TNGX icon
75
Tango Therapeutics
TNGX
$4.03B
$5.44M 0.03%
750,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2022 Portfolio in Review

As of Q4 2022, Julian Baker held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Julian Baker added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Julian Baker's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Julian Baker fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Julian Baker's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Julian Baker opened 13 new positions and closed 15 in Q4 2022.
  • Julian Baker's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.